TICKERNERD
Menu
IQVIQVHealthcare · Diagnostics & Research

IQV Stock Forecast: IQVIA Holdings, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$258
−0.72% on the day

The 22 Wall Street analysts covering IQVIA Holdings, Inc. hold a median 12-month price target of $285 — +10.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$43.8B
Ticker Nerd rank
93 / 100
Median analyst target
$285
Analysts covering
22
Revenue$4.4B+8.7% y/y
Operating income$569.0M
Net income$258.0M
Free cash flow$360.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
−3.6%
YTD
+14.5%
1Y
+28.5%
From 52W high
−6.1%
From 52W low
+64.8%
$157
$275
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IQV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IQVIA Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
90
Volatility
88
Revisions
88
Momentum
84
Quality
70
Growth
69
Issuance
68
Accruals
66
Size
6

Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (66): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IQV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IQV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26IQVHigh $345Median $285Low $250

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
19 Buy3 Hold0 Sell
Low $250Median $285High $345

The green dot is the last close — the median target sits +10.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Sept 2026UBSReinstatesBuy$345
29 Sept 2026RBC CapitalMaintainsOutperform$247 → $319
28 Sept 2026Truist SecuritiesReiteratesBuy$300 → $329
17 Sept 2026Morgan StanleyMaintainsEqual-Weight$240 → $270
17 Sept 2026Morgan StanleyMaintainsEqual-Weight—
29 July 2026BairdMaintainsOutperform$252 → $287
29 July 2026BairdMaintainsOutperform—
29 July 2026BMO CapitalMaintainsOutperform—
29 July 2026BMO CapitalMaintainsOutperform$210 → $270
29 July 2026JP MorganMaintainsOverweight$225 → $285
29 July 2026JP MorganMaintainsOverweight—
29 July 2026RBC CapitalMaintainsOutperform$221 → $247
29 July 2026RBC CapitalMaintainsOutperform—
29 July 2026StifelMaintainsBuy$220 → $276
29 July 2026StifelMaintainsBuy—
29 July 2026TD CowenMaintainsBuy—
29 July 2026TD CowenMaintainsBuy$233 → $288
13 July 2026MizuhoMaintainsOutperform$215 → $230
13 July 2026MizuhoMaintainsOutperform—
1 July 2026BairdMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IQV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IQV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, IQVIA Holdings, Inc. returned +28.5% against +17.4% for the S&P 500, dividends included.

IQV vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130140Jan 26Apr 26Jul 26Oct 26IQVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IQV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.2%
Analysts raising
21
Analysts cutting
0
Fundamentals

IQVIA Holdings, Inc. (IQV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.1×

Cheaper than 23% of US stocks

Price / sales
2.6×

Cheaper than 45% of US stocks

Price / book
7.1×

Cheaper than 14% of US stocks

EV / EBITDA
19.1×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
8.7%

Higher than 48% of US stocks

Earnings growth (YoY)
−3.8%

Higher than 32% of US stocks

Gross margin
32.9%

Higher than 38% of US stocks

Operating margin
13.0%

Higher than 70% of US stocks

Net margin
8.1%

Higher than 66% of US stocks

Returns & dividend
Return on equity
22.8%

Higher than 84% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IQVIA Holdings, Inc. (IQV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IQVIA Holdings, Inc. has a market value of $43.8B and an enterprise value of $58.1B.

  • Revenue in the twelve months to 30 June 2026: $17.0B. The latest quarter grew 8.7% year on year.

  • Net income over the same four quarters: $1.4B, a 8.1% net margin.

  • Diluted earnings per share, trailing twelve months: $8.06.

  • Free cash flow in the twelve months to 30 June 2026: $2.2B.

  • IQVIA Holdings, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 164.6M.

  • Trailing P/E: 33.1×; forward P/E: 18.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • IQVIA Holdings, Inc. employs 94,000 people — $181K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

IQV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IQVIQVIA Holdings, Inc.$43.8B
93
WATWaters Corp.$42.8B
53
ILMNIllumina, Inc.$41.3B
95
IDXXIDEXX Laboratories, Inc.$41.2B
92
AAgilent Technologies, Inc.$48.0B
87
NTRANatera, Inc.$55.3B
80
MTDMettler-Toledo International, Inc.$31.3B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IQVIA Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IQV news & analysis

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

Business Wire · 7 Oct 2026positive

IQVIA introduced IQVIA Life Science Models at TechIQ 2026, a suite of purpose-built models designed to help life sciences companies predict clinical trial outcomes. The suite combines IQVIA’s proprietary expert content and deep domain knowledge.

Why it matters — The launch highlights a new IQVIA offering focused on supporting clinical trial outcome prediction for life sciences companies.

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

Business Wire · 7 Oct 2026positive

IQVIA introduced IQVIA Explorer at TechIQ 2026, describing it as a tool that turns one-time analytics projects into an always-on commercial intelligence capability to help customers make better-informed commercial decisions.

Why it matters — IQV watchers may note the launch as an expansion of IQVIA’s commercial intelligence offering for life sciences customers.

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

Zacks Investment Research · 2 Oct 2026positive

Zacks Investment Research highlighted IQVIA's extensive healthcare database, AI-enabled capabilities, and strong R&D bookings as supporting growth, while noting low liquidity and $14.1 billion in net debt remain areas of focus for the company.

Why it matters — IQVIA watchers would focus on the balance between the company's growth drivers—its database, AI capabilities, and R&D bookings—and the financial headwinds of low liquidity and substantial net debt.

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

Business Wire · 29 Sept 2026neutral

IQVIA announced it will release its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026, and will host a conference call and webcast at 9:00 a.m. Eastern Time the same day. The earnings release will accompany the announcement.

Why it matters — IQVIA watchers will care because this sets the date and logistics for the company's upcoming quarterly earnings report and management webcast.

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

Zacks Investment Research · 16 Sept 2026positive

IQVIA's stock has risen approximately 60% over the past six months. The company's accelerating organic growth, robust R&D bookings, and expanding AI adoption are cited as strengthening its demand visibility and business momentum.

Why it matters — The report signals that IQVIA is experiencing strengthening demand visibility and momentum across its growth drivers, which is relevant to investors tracking the company's performance.

FAQ

Frequently asked questions about IQV stock

What is the IQV stock price forecast for 2026-2027?

The 22 Wall Street analysts covering IQVIA Holdings, Inc. have a median 12-month price target of $285, with estimates ranging from $250 to $345. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IQV stock a buy right now?

Of the 22 analysts covering IQVIA Holdings, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IQVIA Holdings, Inc. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IQV?

As at 6 Oct 2026, IQVIA Holdings, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).

Will IQV stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +10.4% from the last close, and Ticker Nerd's factor model ranks IQVIA Holdings, Inc. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IQV stock forecast for 2030?

No analyst covering IQVIA Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IQV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $250 to $345 over the next 12 months.

How has IQV stock performed over the past year?

IQVIA Holdings, Inc. returned +28.5% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IQVIA Holdings, Inc. do?

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence.

What is the latest news on IQV?

The most recent item we track (Business Wire, 7 Oct 2026): "IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes". IQVIA introduced IQVIA Life Science Models at TechIQ 2026, a suite of purpose-built models designed to help life sciences companies predict clinical trial outcomes. The suite combines IQVIA’s proprietary expert content and deep domain knowledge.

Company

About IQVIA Holdings, Inc.

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence. The company combines advanced data, technology solutions, and domain expertise to help pharmaceutical, biotechnology, medical device, and healthcare organizations improve clinical development, evidence generation, and commercial execution. Its core business spans technology and analytics solutions, research and development solutions, and contract sales and medical solutions, making it a key partner across the medical product lifecycle. IQVIA Holdings Inc. serves clients in major regions worldwide, including the Americas, Europe, Africa, and the Asia-Pacific, and plays an important role in turning health data into actionable insights for research, operations, and market access.

CEO Mr. Ari Bousbib · 94,000 employees · United States · https://www.iqvia.com